Devices and Methods for Prognosis Prediction for Melanoma Cancer

摘要

The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.

主权项

1. A method for predicting the prognosis of a melanoma in a patient with stage IIIB or stage IIIC cutaneous melanoma after lymphadenectomy, comprising:
measuring from a tumor sample from said patient, expression of mRNA for the genes:
milk fat globule EGF factor 8 protein (MFGE8);isocitrate dehydrogenase 1 (NADPH+soluble (IDH1);paired immunoglobin-like type 2 receptor alpha (PILRA);major histocompatibility complex class 1E (HLA-E); andthioredoxin domain containing 5 (TXNDC5); where said expression of each of said genes from a sample from a patient is determined using qPCR to quantify mRNA expression; and calculating a score (“qPS”) according to the formula:
qPS=−[1328.15−187.42(IDH1)+137.10(MFGE8)+73.61(PILRA)+211.22(HLA-E)+143.94(TXNDC5)],where in said formula, IDH1 means ΔΔCt for isocitrate dehydrogenase 1, MFGE8 means ΔΔCt for milk fat globule EGF factor 8 protein, PILRA means ΔΔCt for paired immunoglobin-like type 2 receptor alpha, HLA-E means ΔΔCt for major histocompatibility complex, class 1E, and TXHDC5 means ΔΔCt for thioredoxin domain containing 5;
wherein a qPS score of less than zero indicates poor prognosis with respect to time to progression and overall survival and a qPS score of greater than zero indicates good prognosis with respect to time to progression and overall survival; and where the expression of IDH1 is measured using: a forward oligonucleotide primer for IDH1 having the sequence of SEQ ID NO.1, and a reverse oligonucleotide primer for IDH1 having the sequence of SEQ ID NO.2.